These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 22169623)

  • 1. Identification of the heparin binding site on adeno-associated virus serotype 3B (AAV-3B).
    Lerch TF; Chapman MS
    Virology; 2012 Feb; 423(1):6-13. PubMed ID: 22169623
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-function analysis of receptor-binding in adeno-associated virus serotype 6 (AAV-6).
    Xie Q; Lerch TF; Meyer NL; Chapman MS
    Virology; 2011 Nov; 420(1):10-9. PubMed ID: 21917284
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification of amino acid residues in the capsid proteins of adeno-associated virus type 2 that contribute to heparan sulfate proteoglycan binding.
    Opie SR; Warrington KH; Agbandje-McKenna M; Zolotukhin S; Muzyczka N
    J Virol; 2003 Jun; 77(12):6995-7006. PubMed ID: 12768018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy.
    Xie Q; Bu W; Bhatia S; Hare J; Somasundaram T; Azzi A; Chapman MS
    Proc Natl Acad Sci U S A; 2002 Aug; 99(16):10405-10. PubMed ID: 12136130
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential adeno-associated virus serotype-specific interaction patterns with synthetic heparins and other glycans.
    Mietzsch M; Broecker F; Reinhardt A; Seeberger PH; Heilbronn R
    J Virol; 2014 Mar; 88(5):2991-3003. PubMed ID: 24371066
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adeno-associated virus-2 and its primary cellular receptor--Cryo-EM structure of a heparin complex.
    O'Donnell J; Taylor KA; Chapman MS
    Virology; 2009 Mar; 385(2):434-43. PubMed ID: 19144372
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism.
    Perabo L; Goldnau D; White K; Endell J; Boucas J; Humme S; Work LM; Janicki H; Hallek M; Baker AH; Büning H
    J Virol; 2006 Jul; 80(14):7265-9. PubMed ID: 16809332
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of the Adeno-Associated Virus 1 and 6 Sialic Acid Binding Site.
    Huang LY; Patel A; Ng R; Miller EB; Halder S; McKenna R; Asokan A; Agbandje-McKenna M
    J Virol; 2016 Jun; 90(11):5219-5230. PubMed ID: 26962225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions.
    Summerford C; Samulski RJ
    J Virol; 1998 Feb; 72(2):1438-45. PubMed ID: 9445046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural and cellular biology of adeno-associated virus attachment and entry.
    Zengel J; Carette JE
    Adv Virus Res; 2020; 106():39-84. PubMed ID: 32327148
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors.
    Shi W; Arnold GS; Bartlett JS
    Hum Gene Ther; 2001 Sep; 12(14):1697-711. PubMed ID: 11560765
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2.
    Qing K; Mah C; Hansen J; Zhou S; Dwarki V; Srivastava A
    Nat Med; 1999 Jan; 5(1):71-7. PubMed ID: 9883842
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells.
    Nicklin SA; Buening H; Dishart KL; de Alwis M; Girod A; Hacker U; Thrasher AJ; Ali RR; Hallek M; Baker AH
    Mol Ther; 2001 Sep; 4(3):174-81. PubMed ID: 11545607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity.
    Schmidt M; Voutetakis A; Afione S; Zheng C; Mandikian D; Chiorini JA
    J Virol; 2008 Feb; 82(3):1399-406. PubMed ID: 18045941
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular characterization of the heparin-dependent transduction domain on the capsid of a novel adeno-associated virus isolate, AAV(VR-942).
    Schmidt M; Govindasamy L; Afione S; Kaludov N; Agbandje-McKenna M; Chiorini JA
    J Virol; 2008 Sep; 82(17):8911-6. PubMed ID: 18524816
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The structure of adeno-associated virus serotype 3B (AAV-3B): insights into receptor binding and immune evasion.
    Lerch TF; Xie Q; Chapman MS
    Virology; 2010 Jul; 403(1):26-36. PubMed ID: 20444480
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RGD inclusion in VP3 provides adeno-associated virus type 2 (AAV2)-based vectors with a heparan sulfate-independent cell entry mechanism.
    Shi W; Bartlett JS
    Mol Ther; 2003 Apr; 7(4):515-25. PubMed ID: 12727115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection.
    Summerford C; Bartlett JS; Samulski RJ
    Nat Med; 1999 Jan; 5(1):78-82. PubMed ID: 9883843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity.
    Rabinowitz JE; Rolling F; Li C; Conrath H; Xiao W; Xiao X; Samulski RJ
    J Virol; 2002 Jan; 76(2):791-801. PubMed ID: 11752169
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Engagement of the B-cell antigen receptor (BCR) allows efficient transduction of ZAP-70-positive primary B-CLL cells by recombinant adeno-associated virus (rAAV) vectors.
    Kofler DM; Büning H; Mayr C; Bund D; Baumert J; Hallek M; Wendtner CM
    Gene Ther; 2004 Sep; 11(18):1416-24. PubMed ID: 15269708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.